Skip to main content
Back
Watch Compare

Cadrenal Therapeutics, Inc.

Data quality: 83%
CVKD
Nasdaq Manufacturing Chemicals
$4.76
▼ $0.21 (-4.23%)
Mkt Cap: 12.19 M
Price
$4.86
Mkt Cap
12.19 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -12.61 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-376.39%
Below sector avg (-53.34%)
ROIC-302.38%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio3.02
Interest CoverageN/A

Valuation

PE (TTM)
-0.92
Above sector avg (-1.47)
P/B Ratio4.46
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.9 -1.5
P/B 4.5 1.6
ROE % -376.4 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

3 analysts
Buy
Current
$4.76
+481.2%
Target
$27.67
$13.00
$25.00
$45.00
Forecast
Forward P/E -1.22
Forward EPS -$3.91
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$3.91
-$3.91 – -$3.91
 0.0 1
FY2026 -$5.88
-$7.74 – -$4.01
 0.0 2

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$1.21 -$1.41 -16.5%
Q32025 -$1.55 -$1.31 +15.5%
Q22025 -$1.78 -$1.87 -5.4%
Q12025 -$2.15 -$2.09 +2.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -13.24 M
ROE -376.39% ROA -263.01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.61 M
ROIC -302.38% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.02
Interest Coverage N/A Asset Turnover N/A
Working Capital 2.73 M Tangible Book Value 2.73 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.92 Forward P/E N/A
P/B Ratio 4.46 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -103.44%
Market Cap 12.19 M Enterprise Value 8.33 M
Per Share
EPS (Diluted TTM) -6.64 Revenue / Share N/A
FCF / Share -5.03 OCF / Share -5.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 95.24%
SBC-Adj. FCF -14.52 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Revenue — — — —
Net Income -13.24 M -10.65 M -6.71 M -8.36 M
EPS (Diluted) -6.64 -8.73 -0.85 -0.62
Gross Profit — — — —
Operating Income -13.46 M -10.96 M -2.70 M -7.63 M
EBITDA — — — —
R&D Expenses 4.10 M 4.21 M 136,802.0 4.08 M
SG&A Expenses — — — —
D&A — — — —
Interest Expense — 3,534.0 40,192.0 —
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2022 FY2023
Total Assets 4.33 M 10.12 M 778,174.0 8.52 M
Total Liabilities 1.59 M 2.68 M 6.33 M 826,875.0
Shareholders' Equity 2.74 M 7.44 M -5.55 M 7.69 M
Total Debt — — — —
Cash & Equivalents 4.01 M 10.00 M — 8.40 M
Current Assets 4.32 M 10.11 M 727,596.0 8.49 M
Current Liabilities 1.59 M 2.68 M 1.33 M 826,875.0